EnviroTech :: Biotech
Boehringer Ingelheim to Enter Biosimilars Business
1:17 AM MDT | September 27, 2011 | Deepti Ramesh
Boehringer Ingelheim (Ingelheim, Germany) says it will establish a new separate business for the development and commercialization of biosimilars. Biosimilars are approved versions of innovator biopharmaceutical products introduced after patent expiry. “We believe that biosimilars will become a major part of the biopharmaceutical market and will enable many more patients access to important medicines,” says Wolfram Carius, member of the board of managing directors and responsible for operations at Boehringer Ingelheim. The company will leverage its...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee